

Review article

Stem Cell Conditioned Medium as a Novel Treatment for Neuroinflammation Diseases

Shima Mehrabadi 2, Seyed Shahabeddin Sadr 1,2*

1. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

2. Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

*correspondence: **Seyed Shahabeddin Sadr**, Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Email: shahabsadr2012@yahoo.com

Abstract:

Inflammation is a most important factor that mentioned as causes of many neurodegeneration disease like Parkinson, Alzheimer and ALS. Neuroinflammation is poorly understood like neuroinflammation in Alzheimer and Parkinson. Studies showed that even chronic peripheral inflammation that observe in many diseases like arthritis can cause neurodegeneration and dementia in some cases. The neuroinflammation in many dementia diseases are local and information is limited about it. One of the most important treatments for dementia diseases like Alzheimer is the use of anti-inflammatory drugs like NSAIDS but unfortunately they have poor therapeutic effects on neuroinflammation. Recent studies investigated that conditioned medium extracted from mesenchymal stem cells have neuromodulator effects even could prevent neurodegeneration in some cases. In this study we review effects of mesenchymal stem cell conditioned medium in different central nervous system (CNS) disease associated with neuroinflammation.

Keywords: Neuroinflammation, Stem cell, Conditioned Medium, Neurodegenerative disease.

Introduction:

Neuroinflammation includes physiological and cellular responses of the nervous system to damage, infection or neurodegenerative diseases(1). Actually neuroinflammation is a complex response involving the activation of glia, release of inflammatory cytokines and chemokines, and generation of reactive oxygen and nitrogen species(2). Microglia is the innate immune system of the central nervous system and are key cellular mediators of neuroinflammatory processes. Some chronic/remitting neurological diseases, such as multiple sclerosis, have long been recognized as inflammatory, the term neuroinflammation has come to denote chronic, CNS-specific, inflammation-like glial responses that do not reproduce the classic characteristics of inflammation in the periphery but that may engender neurodegenerative events; including plaque formation, dystrophic neurite growth, and excessive tau phosphorylation(3). Also many viral infection could induce neuroinflammation and neurodegeneration in CNS. A virus can enter the CNS through two distinct, including hematogenous dissemination which the virus gains access to the brain by BBB and neuronal retrograde dissemination (4, 5). Viral infections are associated with highly secreted cytokines, cholesterol increase, elevations of lipopolysaccharide (LPS) concentration, insulin resistance and testosterone deficiency(6), which are all involved in inflammation of the CNS. Chronic low grade inflammation with changes in brain structure that could precipitate neurodegenerative changes associated with Alzheimer's disease and

other dementias. For example, neuronal loss is a common feature of major depression and dementia(7). Actually Oxidative stress and chronic neuroinflammation are key pathologic factors in brain aging and neurodegenerative diseases, such as Alzheimer, ALS and Parkinson's diseases. As physiological signaling molecules, reactive oxygen species (ROS) play important roles in many biological processes, but increasing amount of ROS can activate microglia and astrocyte in brain and release inflammatory factors in brain and induce neurodegeneration in CNS (8). There are no specific drugs available to repair loss of neurons, induce neuroregeneration and prevent further neurodegeneration in Alzheimer, Parkinson, ALS and MS patients(9). Current drugs are effective only in reducing the severity of symptoms by limiting the extent of neuroinflammation in these patients(10). Nonsteroidal anti-inflammatory drugs (NSAIDs) show neuroprotective and antioxidant effects, inhibit free radicals production, scavenge free radicals and inhibit nuclear factor-kappa B (NF- κ B) and interleukins activation in the CNS(10, 11). But as mentioned NSAIDs can not to induce neuroregeneration and also prevent to neurodegeneration. They just could slow down progress of neuroinflammations in these patients(10). For these reason nowadays researcher are finding a way to stop neuroinflammation in CNS. In among of research, studies showed that conditioned medium extracted from stem cells have anti-inflammatory effect (12-14). Actually stem cell release neuromodulator compounds to their environment that could be use for

healing of inflammation. We gathered valuable data about effects of stem cell conditioned medium in all of neuroinflammation associated disease to discuss about the advantage and disadvantages of stem cell conditioned medium use in neuroinflammation.

1- Therapeutic effects of Stem cell conditioned medium:

Stem cell therapy are used widely in many disease models (15, 16). There are several problems determined by the long-term use of stem cell-based therapies, including improvements in the survival, engraftment, proliferation, and regeneration of stem cells(17). Recent studies have shown that the majority of donor cell death occurs in the first hours to days after transplantation(18). Also stem cells therapy cannot provide an immediate treatment because of the long waiting time for cell preparation and proliferation (19, 20). As well as certain studies have suggested that the transplantation of stem cells into normal tissues may cause tumor formation (21, 22). Many number of studies have suggested that the principal beneficial effects of stem cells especially Mesenchymal stem cells are likely mediated via paracrine mechanisms rather than replication or differentiation (23, 24). The use of secretome Conditioned medium (CM) has several advantages compared to the use of stem cells, as CM can be manufactured, freeze-dried, packaged, and transported more easily. Moreover, as it is devoid of cells; there is no need to match the donor and the recipient to avoid rejection problems(25). Also CM from Mesenchymal stem cells contains various

cytokines, growth factors and microRNAs, which has important roles in modulating the inflammation and can be used instead of stem cell therapy in some cases(26). Neurotrophic factors in CM could access affected neurons in CNS by either directly crossing the blood brain barrier or through the retrograde transport mechanism in CNS(27). Stem cells conditioned medium exert immuneomodulatory functions, including inhibition of microglia and astrocyte function. Mesenchymal stromal cells (MSCs) respond to the inflammatory environment by enhancing expression of immunosuppressive factors thereby influencing target cells through paracrine mechanisms(28). Conditioned medium of MSCs contain of signalling molecules such as TGF- β , IL-10, CCL9, IFN- α , IFN- β , nitric oxide (NO), VEGF, FGF, HGF, PDGF and membrane-bound vesicles, including microvesicles and exosomes that can be used as anti-inflammatory substance and even regeneration of tissue (29-32).

2- Stem cell Conditioned medium effects in Alzheimer:

Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by a decline in cognitive abilities and the appearance of β -amyloid plaques in the brain. Although the cause of Alzheimer disease is not understood clearly, activated microglia and releasing many pro inflammatory cytokines have the most important role of neuroinflammation and neurodegeneration in Alzheimer disease(33-35).Studies showed that conditioned medium from various stem cells have a lot of neurotrophic factors(36). Studies showed

that brain derived neurotrophic factor (BDNF) and hepatic growth factor (HGF) extracted from CM supports neuronal survival and plasticity and is involved in learning and memory formation(37-39). Also BDNF inhibits microglial activation and promotes axonal regeneration(38). Matrix metalloproteinase-9 (MMP-9) in CM from the stem cells of human exfoliated deciduous teeth reduces the level of pathogenic A β oligomers in AD mice and restores synaptic and cognitive deficits in these mice (40), and also growth factor- β (TGF- β) modulates microglial activation in these CM and could attenuate neuroinflammation in AD model in mice (40). In another study indicated that adipose-derived stem cell of CM can improve antidepressant-related behaviors in AD model in mice. This may extend usage of CM to not only regenerative medicine but psychological illness(41). Microglia play a crucial role in disease pathogenesis during neurodegenerative diseases such as Alzheimer's disease(42). M1 phenotype of microglia exerts toxic effects by secreting proinflammatory cytokines such as tumor necrosis factor (TNF- α), interleukin (IL)-1 β , IL-6, and nitric oxide (NO) and plays a role as a major component of the neuroinflammatory response but M2 phenotype is involved in the maintenance of CNS homeostasis, phagocytizing apoptotic bodies, releasing neurotrophic factors, and reducing proinflammatory cytokines (43). Mesenchymal stem cell conditioned medium can modulate microglial function via TGF- β (44) and induce microglia into M2 phenotype and promoted A β -phagocytosis

so reduce A β plaques in AD mouse models(45).

3- Stem cell Conditioned medium effects in Amyotrophic Lateral Sclerosis (ALS):

Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease, known as motor neuron disease is defined by progressive loss of motor neurons, resulting in paralysis and death (46, 47). Oxidative stress and motor neuron excitotoxic death have been linked to neuroinflammatory responses, like elevations of pro-inflammatory cytokines in the CNS(48, 49), astrocyte (50) and microglia activation(51). These pathogenic properties are thought to play important roles in motor neuron death and ALS progression. In another study showed that lifespan in ALS model of mice following adipose stem cell conditioned medium (ASC-CM) administration was increased and correlated with increased in numbers of motor neuron survival in the spinal cord lumbar area(52). Also ASC-CM could prevent early disease pathology, which supports its use in familial ALS. These data emphasize that early identification in at-risk populations for developing ALS is more effectiveness (53). MSC secrete a variety of cytokines and growth factors(54). Evidence from preclinical studies suggested the neuroprotective effects of MSCs seem to be mainly based on anti-inflammatory and immunomodulatory activities of these cells (54). MSC have already been used in ALS patients in a clinical phase I - trial and few adverse effects have been observed which is in favor of further clinical evaluation of this approach and it's more safe if we use MSC-CM instead of MSC as we mentioned CM is

effectiveness as MSC because of neuromodulatory and neuroprotective composition with less adverse effects (55, 56). Also Data indicate that MSC-CM exerts a protective role against in vitro induced apoptosis in different cell types (primary motor neurons and astrocytes) and maintains its protective potential in motor neurons. This function may involve the activation of both MAPK/Erk1/2 and PI3K/Akt pathways. The regulation of astrocytic neurotrophic factor expression and secretion contributes to MSC-mediated neuroprotection in ALS(57).

4- Stem cell Conditioned medium effects in Parkinson disease:

Parkinson's disease (PD) is one of the most famous of neurodegenerative disease. This disease is hallmark with loss of dopaminergic neurons in specific region of midbrain that named substantia nigra pars compacta (SNpc). Motor and psychological disorders of PD are caused by dopamine loss of corpus striatum as the result of nigrostriatal pathway degeneration (58-61). Chronic neuroinflammation is one of the hallmarks of PD pathophysiology. Post-mortem analyses of human PD patients and experimental animal studies indicate that activation of glial cells and increases in pro-inflammatory factor levels are in the PD brain(61).Studies showed that CM could improve PD symptoms. For example in one study ASC-CM protects from dopaminergic neurons in PD. Neuroprotection by ASC-CM was associated with stimulation of BDNF and NT3 genes expression and tyrosine hydroxylase positive (TH+) neurons preservation(62). BDNF is a neurothrophic factor that is very important

for growth and survival of neurons of the SNpc. Reduced expression of BDNF within the SNpc has been shown to cause the loss of dopaminergic neurons in PD(63). Also in another study conditioned medium taken from epithelial cells of choroid plexus (CPECs-CM) was capable of inducing neuronal and dopaminergic differentiation of umbilical cord mesenchymal stem Cells (UCMSCs). Actually CM factors provides signaling molecules for proliferation of neural progenitor cells required for neurogenesis in dopaminergic neurons(64). In a rat model for PD, the efficacy of neurotrophic factors from stem cells was superior to that of mesenchymal stem cells in terms of behavioral, biochemical, and histological indices. Also surviving cells migrated toward the lesion in SNpc is more in the presence of CM of MSC and had the most significant effect at the end of the migration trail. Stromal cell-derived factor-1alpha (SDF-1alpha) is also reported as one of chemokines released from MSCs. SDF-1alpha in CM of MSC increased DA release and suppressed cell death by decline of 6-hydroxydopamine (6-OHDA). 6-OHDA is a neurotoxic compound that destroy dopamine and noradrenaline and recently been found to be formed endogenously in patients suffering from PD(65). So MSC secretome has neuroprotective effects by SDF-1 and 6-OHDA and also many neurotrophic factors in CM that inhibit degeneration of DA neurons in PD models.

5- Stem cell Conditioned medium effects in Multiple Sclerosis:

Multiple sclerosis (MS) is a long-term and autoimmune disease that attacks the central

nervous system, affecting the brain, spinal cord, and optic nerves(66). MS is characterized by neuroinflammation, demyelination and axonal loss. In one study showed single i.v. injection of stem cell of human exfoliated deciduous conditioned medium (SHED-CM) reduced the severity of encephalomyelitis (EAE) that is a model for MS by suppressing the neuroinflammation, demyelination, and axonal injury associated with this disease(67). Also Analysis of the spinal cord of treated mice with SHED-CM showed that induced a shift in the macrophage phenotype from an M1 proinflammatory phenotype to an M2 anti-inflammatory phenotype, as well as suppressed the expression of proinflammatory mediators(67). In a clinical study, both bone marrow mesenchymal stem cell conditioned medium (BMSC-CM) is safe with relative efficacy in stabilizing the disease and reversing symptoms(68). In another study investigated indoleamine 2,3-dioxygenase, IL-6, PGE2, LIF, and HGF, contribute to the immunosuppressive effects of MSCs(69, 70). HGF, in particular, is thought to be the critical factor in human BMMSC-CM that promotes tissue regeneration and drives the anti-proliferative effect on T cells(71). The effects of both HGF in CM are mediated through the tyrosine kinase receptor cMet and mediate enhanced myelin repair as well as immunomodulation(71). These studies raise the possibility that the HGF/cMet pathway may provide novel therapeutic opportunities for the treatment of MS. In another study also showed that the immunomodulating activity by conditioned medium from ASC-CM that could be considered as a promising

tool in MS therapy(72). Actually analysis revealed that MSCs express a number of proteins that modulate immune responses, cell migration, cell proliferation, and CNS repairing, but the exact composition of CM is more complicated than initially envisioned and remains to be elucidated(73). Also in another study IL-37 in MSCs-CM decrease EAE and modulates the balance between pro- and anti-inflammatory cytokines, that IL-37 could be a promising tool in MS management(74). Actually there is a significant down-regulation of its expression in spinal cord from mice with EAE, which was restored by MSCs-CM treatment. Also a significant reduction of the pro-inflammatory cytokines observed in mice with EAE that treated with MSCs-CM(74).

Conclusion:

This review collect many studies about the benefits of CM administration in neuroinflammatory and neurodegenerative diseases (Fig.1.) . CM has a lot of anti-inflammatory cytokines and it has been proven as an inflammatory modulation composition. Despite a great number of promising results in stem cell-CM , and the urgency of having an efficient treatment to patients who suffer from neurodegenerative diseases, we caution on the use of CM in clinical trials, because there remains a lack of understanding of the effect of these composition on brain tissue and more studies are necessary in clinical trials on neurological diseases, to make sure that these CM do not have the potential to cause severe adverse effects in humans and also we need to try CM of different stem cells to

achieve for maximum effect of healing in neurodegenerative diseases.

References:

1. Bazan NG, Halabi A, Ertel M, Petasis NA. Chapter 34 - Neuroinflammation A2 - Brady, Scott T. In: Siegel GJ, Albers RW, Price DL, editors. Basic Neurochemistry (Eighth Edition). New York: Academic Press; 2012. p. 610-20.
2. Milatovic D, Zaja-Milatovic S, Breyer RM, Aschner M, Montine TJ. Chapter 64 - Neuroinflammation and oxidative injury in developmental neurotoxicity A2 - Gupta, Ramesh C. Reproductive and Developmental Toxicology. San Diego: Academic Press; 2011. p. 847-54.
3. Streit WJ, Mrak RE, Griffin WST. Microglia and neuroinflammation: a pathological perspective. *Journal of neuroinflammation*. 2004;1(1):14.
4. Yang W-X, Terasaki T, Shiroki K, Ohka S, Aoki J, Tanabe S, et al. Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor. *Virology*. 1997;229(2):421-8.
5. Aronsson F, Robertson B, Ljunggren H-G, Kristensson K. Invasion and persistence of the neuroadapted influenza virus A/WSN/33 in the mouse olfactory system. *Viral immunology*. 2003;16(3):415-23.
6. Brew BJ, Crowe S, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. *Journal of Neuroimmune Pharmacology*. 2009;4(2):163.
7. Leonard BE. Inflammation, depression and dementia: are they connected? *Neurochemical research*. 2007;32(10):1749-56.
8. Gao H-M, Zhou H, Hong J-S. Oxidative stress, neuroinflammation, and neurodegeneration. *Neuroinflammation and Neurodegeneration*: Springer; 2014. p. 81-104.
9. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. *Cell*. 2010;140(6):918-34.
10. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature*. 2013;501(7465):45.
11. Schwartz M, Deczkowska A. Neurological disease as a failure of brain-immune crosstalk: the multiple faces of neuroinflammation. *Trends in immunology*. 2016;37(10):668-79.
12. Rajan TS, Giacoppo S, Trubiani O, Diomede F, Piattelli A, Bramanti P, et al. Conditioned medium of periodontal ligament mesenchymal stem cells exert anti-inflammatory effects in lipopolysaccharide-activated mouse motoneurons. *Experimental cell research*. 2016;349(1):152-61.
13. Sicco CL, Reverberi D, Balbi C, Ulivi V, Principi E, Pascucci L, et al. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: Endorsement of macrophage polarization. *Stem cells translational medicine*. 2017;6(3):1018-28.
14. Guillen MI, Platas J, del Caz P, Dolores M, Mirabet V, Alcaraz MJ. Paracrine anti-inflammatory effects of

adipose tissue-derived mesenchymal stem cells in human monocytes. *Frontiers in physiology*. 2018;9:661.

15. Ding D-C, Chang Y-H, Shyu W-C, Lin S-Z. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. *Cell transplantation*. 2015;24(3):339-47.

16. Golpanian S, Schulman IH, Ebert RF, Heldman AW, DiFede DL, Yang PC, et al. Concise review: review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease. *Stem cells translational medicine*. 2016;5(2):186-91.

17. Leventhal A, Chen G, Negro A, Boehm M. The benefits and risks of stem cell technology. *Oral diseases*. 2012;18(3):217-22.

18. Robey TE, Saiget MK, Reinecke H, Murry CE. Systems approaches to preventing transplanted cell death in cardiac repair. *Journal of molecular and cellular cardiology*. 2008;45(4):567-81. PubMed PMID: 18466917. Epub 03/19.

19. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. *Stem cell research*. 2011;6(3):206-14.

20. Chimenti I, Smith RR, Li T-S, Gerstenblith G, Messina E, Giacomello A, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circulation research*. 2010;106(5):971-80.

21. Stagg J. Mesenchymal stem cells in cancer. *Stem cell reviews*. 2008;4(2):119-24.

22. Sell S. On the stem cell origin of cancer. *The American journal of pathology*. 2010;176(6):2584-94.

23. Maguire G. Stem cell therapy without the cells. *Communicative & integrative biology*. 2013;6(6):e26631.

24. Vizoso F, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. *International journal of molecular sciences*. 2017;18(9):1852.

25. Pawitan JA. Prospect of stem cell conditioned medium in regenerative medicine. *BioMed research international*. 2014;2014.

26. . !!! INVALID CITATION !!! .

27. Zheng C, Nennesmo I, Fadeel B, Henter JJ. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 2004;56(4):564-7.

28. Grogan SP, Barbero A, Diaz-Romero J, Cleton-Jansen AM, Soeder S, Whiteside R, et al. Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 2007;56(2):586-95.

29. Hoseini SJ, Ghazavi H, Forouzanfar F, Mashkani B, Ghorbani A, Mahdipour E, et al. Fibroblast growth factor 1-transfected adipose-derived mesenchymal stem cells

promote angiogenic proliferation. DNA and cell biology. 2017;36(5):401-12.

30. Wu SZ, Li YL, Huang W, Cai WF, Liang J, Paul C, et al. Paracrine effect of CXCR4-overexpressing mesenchymal stem cells on ischemic heart injury. Cell biochemistry and function. 2017;35(2):113-23.

31. Cui C, Cui Y, Gao J, Li R, Jiang X, Tian Y, et al. Intraparenchymal treatment with bone marrow mesenchymal stem cell-conditioned medium exerts neuroprotection following intracerebral hemorrhage. Molecular medicine reports. 2017;15(4):2374-82.

32. Xiang J, Hu J, Shen T, Liu B, Hua F, Zan K, et al. Bone marrow mesenchymal stem cells-conditioned medium enhances vascular remodeling after stroke in type 2 diabetic rats. Neuroscience letters. 2017;644:62-6.

33. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68(2):270-81.

34. Citron M. Alzheimer's disease: strategies for disease modification. Nature reviews Drug discovery. 2010;9(5):387.

35. Swomley AM, Förster S, Keeney JT, Triplett J, Zhang Z, Sultana R, et al. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2014;1842(8):1248-57.

36. Uchida S, Inanaga Y, Kobayashi M, Hurukawa S, Araie M, Sakuragawa N. Neurotrophic function of conditioned medium from human amniotic epithelial cells. Journal of neuroscience research. 2000;62(4):585-90.

37. Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Progress in brain research. 128: Elsevier; 2000. p. 231-41.

38. Iannotti C, Li H, Yan P, Lu X, Wirthlin L, Xu X-M. Glial cell line-derived neurotrophic factor-enriched bridging transplants promote propriospinal axonal regeneration and enhance myelination after spinal cord injury. Experimental neurology. 2003;183(2):379-93.

39. Niimura M, Takagi N, Takagi K, Mizutani R, Tanonaka K, Funakoshi H, et al. The protective effect of hepatocyte growth factor against cell death in the hippocampus after transient forebrain ischemia is related to the improvement of apurinic/apyrimidinic endonuclease/redox factor-1 level and inhibition of NADPH oxidase activity. Neuroscience letters. 2006;407(2):136-40.

40. Mita T, Furukawa-Hibi Y, Takeuchi H, Hattori H, Yamada K, Hibi H, et al. Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer's disease. Behavioural Brain Research. 2015;293:189-97.

41. Yamazaki H, Jin Y, Tsuchiya A, Kanno T, Nishizaki T. Adipose-derived stem cell-conditioned medium ameliorates antidepressant-related behaviors in the mouse model of Alzheimer's disease. Neuroscience letters. 2015;609:53-7.

42. Lee CD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. Journal of neural transmission. 2010;117(8):949-60.

43. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. *Nature Reviews Immunology*. 2011;11(11):775.
44. Noh MY, Lim SM, Oh K-W, Cho K-A, Park J, Kim K-S, et al. Mesenchymal Stem Cells Modulate the Functional Properties of Microglia via TGF- β Secretion. *Stem cells translational medicine*. 2016;5(11):1538-49.
45. Iwahara N, Yokokaw K, Saito T, Fujikura M, Manabe T, Matsushita T, et al. Mesenchymal stem cell-conditioned medium induces microglia into M2 phenotype and promotes amyloid β -phagocytosis. *Journal of the Neurological Sciences*. 2017;381:665.
46. Appel SH, Zhao W, Beers D, Henkel J. The microglial-motoneuron dialogue in ALS. *Acta Myologica*. 2011;30(1):4.
47. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1985;18(3):271-80.
48. Almer G, Guégan C, Teismann P, Naini A, Rosoklija G, Hays AP, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 2001;49(2):176-85.
49. Wu D-C, Ré DB, Nagai M, Ischiropoulos H, Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. *Proceedings of the National Academy of Sciences*. 2006;103(32):12132-7.
50. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. *Nature neuroscience*. 2008;11(3):251.
51. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. *Science*. 2006;312(5778):1389-92.
52. Fontanilla CV, Gu H, Liu Q, Zhu TZ, Zhou C, Johnstone BH, et al. Adipose-derived stem cell conditioned media extends survival time of a mouse model of amyotrophic lateral sclerosis. *Scientific reports*. 2015;5:16953.
53. Walker LC, Meadows MR, Du Y, March LK, Jones JK. Adipose-derived stem cell conditioned medium impacts asymptomatic peripheral neuromuscular denervation in the mutant superoxide dismutase (G93A) transgenic mouse model of amyotrophic lateral sclerosis. *Restorative neurology and neuroscience*. 2018 (Preprint):1-7.
54. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. *Journal of cellular biochemistry*. 2006;98(5):1076-84.
55. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. *Experimental neurology*. 2010;223(1):229-37.
56. Mazzini L, Mareschi K, Ferrero I, Miglioretti M, Stecco A, Servo S, et al.

Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. *Cytotherapy*. 2012;14(1):56-60.

57. Sun H, Bénardais K, Stanslowsky N, Thau-Habermann N, Hensel N, Huang D, et al. Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in amyotrophic lateral sclerosis (ALS)-in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. *PloS one*. 2013;8(9):e72926.

58. . Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1 α : ; 2011.

59. Lindvall O, Björklund A. Cell therapy in Parkinson's disease. *NeuroRx*. 2004;1(4):382-93.

60. Treciokas LJ, Ansel RD, Markham CH. One to two year treatment of Parkinson's disease with levodopa. *California medicine*. 1971;114(5):7.

61. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. *Translational Neurodegeneration*. 2015;4(1):19.

62. Nakhaeifard M, Haji MGK, Goudarzi I, Rezaei A. Conditioned Medium Protects Dopaminergic Neurons in Parkinsonian Rats. *Cell journal*. 2018;20(3):348-54.

63. Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia

nigra pars compacta. *Journal of Neuroscience*. 2005;25(26):6251-9.

64. Aliaghaei A, Gardaneh M, Maghsoudi N, Salehinejad P, Gharib E. Dopaminergic Induction of Umbilical Cord Mesenchymal Stem Cells by Conditioned Medium of Choroid Plexus Epithelial Cells Reduces Apomorphine-Induced Rotation in Parkinsonian Rats. *Archives of Iranian Medicine (AIM)*. 2016;19(8).

65. Glinka Y, Gassen M, Youdim M. Mechanism of 6-hydroxydopamine neurotoxicity. *Advances in Research on Neurodegeneration: Springer*; 1997. p. 55-66.

66. Wootla B, Eriguchi M, Rodriguez M. Is multiple sclerosis an autoimmune disease? *Autoimmune diseases*. 2012;2012.

67. Shimojima C, Takeuchi H, Jin S, Parajuli B, Hattori H, Suzumura A, et al. Conditioned medium from the stem cells of human exfoliated deciduous teeth ameliorates experimental autoimmune encephalomyelitis. *The Journal of Immunology*. 2016;1501457.

68. Dahbour S, Jamali F, Alhattab D, Al-Radaideh A, Ababneh O, Al-Ryalat N, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. *CNS neuroscience & therapeutics*. 2017;23(11):866-74. PubMed PMID: 28961381. Epub 09/29.

69. Rasmusson I. Immune modulation by mesenchymal stem cells. *Experimental cell research*. 2006;312(12):2169-79.

70. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2, 3-dioxygenase production by human dendritic

cells results in the inhibition of T cell proliferation. The Journal of Immunology. 2000;164(7):3596-9.

71. Bai L, Lennon DP, Caplan AI, DeChant A, Hecker J, Kranso J, et al. Hepatocyte growth factor mediates MSCs stimulated functional recovery in animal models of MS. Nature neuroscience. 2012;15(6):862.

72. Yousefi F, Ebtekar M, Soudi S, Soleimani M, Hashemi SM. In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis. Immunology letters. 2016;172:94-105.

73. Pereira T, Ivanova G, Caseiro AR, Barbosa P, Bártolo PJ, Santos JD, et al. MSCs conditioned media and umbilical cord blood plasma metabolomics and composition. PLoS One. 2014;9(11):e113769.

74. Giacoppo S, Thangavelu SR, Diomedea F, Bramanti P, Conti P, Trubiani O, et al. Anti-inflammatory effects of hypoxia-preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL-37. The FASEB Journal. 2017;31(12):5592-608.

Tables and Charts:

Figure 1: Summary of CM effects on various neurodegenerative and neuroinflammation disease.

